BioSpace News Archive

MOMA Therapeutics and Eli Lilly are both experiencing significant changes in their leadership roster, with one Takeda alum taking the helm at MOMA and an R&D chief at Lilly shooting toward the exit door.

Although Gamestop dominated the financial news this week, surging more than 1,600% in January, Novavax actually saw greater growth in 2020, with year-to-year gains of 2,731% that exceeded those of all the coronavirus stocks.

The next several years will be transformative in the cell and gene therapy space, and Immatics’ Chief Medical Officer Cedrik M. Britten believes his company’s engineered T-cell receptors may play an important role in providing treatment options for cancer patients.

Upjohn Business (1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted (2) Results Full-Year 2020 Revenues of $41.9 Billion, Which Now Exclude Upjohn (1) , Reflect 3% Operational Growth; When the Impact from Consumer Healthcare (1) and the $154 Million of Sales of BNT162b2 are Excluded, Full-Year 2020 Revenues Grew 8% Operationally

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CERC-803 for the treatment of Leukocyte Adhesion Deficiency Type II (LAD-II, also known as SLC35C1-CDG).

The American Academy of Facial Plastic and Reconstructive Surgery, the world’s largest association of facial plastic surgeons, released its 2020 member survey results.

Spectra Medical Devices, Inc. has exciting news to share, our new e-commerce site is now live. “We are proud to offer customers worldwide a new way to shop for our products safely and conveniently. Qualified customers with proper licensing can easily and securely register at our e-commerce site.

Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results

Stilla Technologies is pleased to announce the appointment of Mr. Philippe Mourere as its new Chief Executive Officer. Former CEO and Founder Dr. Rémi Dangla has been appointed Chief Technology Officer and remains a member of the Board of Directors.

Cutera, Inc. (Nasdaq: CUTR ) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today announced that it will report financial results for the fourth quarter and full-year 2020 after the market close on Wednesday, February 17, 2021. The Company’s management will host a conference call to the discuss these results and related matters at 1:30 p.m.